An official website of the United States government
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Trial Status: active
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose
escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy
for the treatment of treatment-naïve subjects with borderline resectable and locally
advanced pancreatic ductal adenocarcinoma (PDAC).
Inclusion Criteria
Imaging consistent with primary PDAC (if PDAC is to be confirmed at study-mandated laparoscopy) or imaging consistent with primary PDAC with prior biopsy/cytology
No radiographic or physical exam evidence of metastatic disease
No prior chemo-, radio-, or surgical therapy for PDAC
Acceptable laboratory values
CA 19-9 <500 U/mL at baseline after biliary decompression
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Ability to provide informed consent
No signs or symptoms of pancreatitis
No other active medical issues which would confound interpretation of safety monitoring, efficacy results or prevent the subject from study participation
Subjects with childbearing potential must agree to use adequate contraception throughout study participation
Exclusion Criteria
Active non-pancreatic cancer that currently requires treatment or is being treated; diagnosis of another malignancy within the past 2 years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancers, or superficial bladder cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment or requires only treatment with luteinizing hormone-releasing hormone agonists or antagonists if initiated at least 30 days prior to screening)
Contraindications or allergies to paclitaxel, PLGA (poly(lactic-co-glycolic ) acid), or contraindications to implantation of PTM-101 or chemotherapies in protocol (e.g., FOLFIRINOX, gemcitabine, nab-paclitaxel)
Known human immunodeficiency virus (HIV) or active viral hepatitis
Active ongoing infection or autoimmune disease which may preclude laparoscopy, placement of PTM-101, administration of chemotherapy or surgical resection of pancreatic tumor
Inability to comply with activities and therapeutic interventions as outlined in the schedule of events
Currently enrolled in another investigational drug or device trial
Women who are pregnant or breastfeeding or who plan to become pregnant or breastfeed; men who plan to donate sperm or conceive a child
Any other medical or surgical conditions, including prior abdominal surgery, that would preclude safe laparoscopy or implantation in the opinion of the investigator
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06673017.
Locations matching your search criteria
United States
Michigan
Detroit
Wayne State University/Karmanos Cancer Institute
Status: Temporarily closed to accrual
Name Not Available
Texas
Houston
M D Anderson Cancer Center
Status: Active
Name Not Available
This is a multi-center, non-randomized, single-arm, open-label, phase Ib dose
escalation/dose expansion study of PTM-101 in subjects with pancreatic ductal
adenocarcinoma (PDAC). Dose escalation will assess the safety of PTM-101 containing
escalating doses of paclitaxel to establish the preliminary Recommended Phase II Dose
(RP2D) when combined with neoadjuvant chemotherapy for subjects who are treatment-naïve,
have borderline resectable or locally advanced PDAC and are eligible for neoadjuvant
chemotherapy. Subsequently, the dose expansion portion will expand the number of subjects
at the preliminary RP2D to assess the efficacy of PTM-101.